Prognostic value of biomarkers in malignant melanoma

Melanoma Research

Volumn 8, Issue 3, 1998, Pages 283-291

  Hernberg, M ^a   Turunen, J P ^a   Von Boguslawsky, K ^b   Muhonen, T ^a   Pyrhonen S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bcl 2; CD4 CD8 ratio; Ki 67; Lymphocyte subsets; Mdm 2; Melanoma immunology; P53; Prognosis; Proliferation markers; Tumour infiltrating lymphocytes

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; BROXURIDINE; DACARBAZINE; KI 67 ANTIGEN; LOMUSTINE; PROTEIN BCL 2; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOCYTE COUNT; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CD4-CD8 RATIO; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MATCHED-PAIR ANALYSIS; MELANOMA; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031838318     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199806000-00013     Document Type: Article

References (29)

1. Ellis P, Makris A, Burton S, et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 1996; 73: 640-643.
2. Florenes VA, Holm R, Fodstad O. Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome. Melanoma Res 1995; 5(3): 183-187.
3. Mooy CM, Luyten GP, de Jong PT, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995; 147(1): 1097-1104.
4. Stretch JR, Gatter KC, Ralfkiaer E, et al. Expression of mutant p53 in melanoma. Cancer Res 1991; 51(21): 5976-5979.
5. Weiss J, Heine M, Korner B, et al. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995; 133(1): 23-31.
6. Gelsleichter L, Gown AM, Zarbo RJ, et al. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995; 8(5): 530-535.
7. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235-2238.
8. Ramsay JA, From L, Iscoe NA, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995; 105(1): 22-26.
9. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995; 17(1): 7-11.
10. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995; 8(2): 150-154.
11. Tron VA, Krajewski S, Klein PH, et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995; 146(3): 643-650.
12. Saenz-Santamaria M, Reed JA, McNutt NS, et al. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutaneous Pathol 1994; 21(5): 393-397.
13. Li Y, McGowan P, Hellstrom I, et al. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153(1): 421-428.
14. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991; 97(2): 197-202.
15. Simony J, Rossi JF, Shishehian B, et al. Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates. Cancer Detect Prev 1991; 15(3): 183-187.
16. Hernberg M, Millionen T, Turunen JP, et al. The CD4+/CD8+ ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma. J Clin Oncol 1996; 14: 1690-1696.
17. Hernberg M, Turunen JP, Muhonen T, et al. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997; 20(6); 488-495.
18. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10(12): 1919-1926.
19. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. In: Gardner MJ, Altman DG, eds. Statistics with Confidence. London: British Medical Journal, 1989: 71-79.
20. Böni R, Doguoglu A, Burg G, et al. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996; 35: 416-418.
21. Vogt T, Zipperer K-H, Vogt A, et al. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57-63.
22. Stone CH, Lynch EF, Linden MD, et al. Immunocytochemical evaluation of proliferating cell nuclear antigen, Ki-67 (MIB-1), and p53 in predicting survival of primary and metastatic malignant melanoma. Appl Immunohistochem 1996; 4(1): 25-33.
23. Reddy VB, Gattuso P, Aranha G, et al. Cell proliferation markers in predicting metastases in malignant melanoma. J Cutaneous Pathol 1995; 22: 248-251.
24. Fanidi A, Harrington FA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359(6395): 554-556.
25. Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57(1): 1-9.
26. McGregor JM, Yu CC-W, Dublin EA, et al. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128: 606-611.
27. Imai Y, Strohmeyer TG, Fleischhacker M, et al. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994; 7(7): 766-770.
28. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69(7): 1237-1245.
29. Poremba C, Yandell DW, Metze D, et al. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 1995; 7: 331-339.